- Home
- LUCY vs BIAF Comparison
LUCY vs BIAF Comparison
Compare LUCY & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LUCY | BIAF |
|---|---|---|
| Founded | 2017 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LUCY | BIAF |
|---|---|---|
| Price | $1.16 | $1.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 183.3K | 140.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $80.76 | N/A |
| Revenue Next Year | $210.34 | $20.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.16 |
| 52 Week High | $5.56 | $13.50 |
Technical Indicators
Market Signals| Indicator | LUCY | BIAF |
|---|---|---|
| Relative Strength Index (RSI) | 46.66 | 51.03 |
| Support Level | $1.01 | $0.97 |
| Resistance Level | $1.24 | $1.08 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 69.16 | 76.00 |
Price Performance
Historical ComparisonAbout LUCY Innovative Eyewear Inc.
Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.